Krebs Biochemicals & Industries Limited (NSE:KREBSBIO)
India · Delayed Price · Currency is INR 64.56
-1.02 (-1.56%)
Jun 22, 2026, 3:29 PM IST
NSE:KREBSBIO Revenue
In the fiscal year ending March 31, 2026, Krebs Biochemicals & Industries had annual revenue of 237.32M INR, down -45.21%. Krebs Biochemicals & Industries had revenue of 68.09M in the quarter ending March 31, 2026, with 11.62% growth.
Revenue
237.32M
Revenue Growth
-45.21%
P/S Ratio
5.82
Revenue / Employee
1.17M
Employees
202
Market Cap
1.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 237.32M | -195.80M | -45.21% |
| Mar 31, 2025 | 433.12M | -71.10M | -14.10% |
| Mar 31, 2024 | 504.22M | -17.13M | -3.29% |
| Mar 31, 2023 | 521.34M | -75.69M | -12.68% |
| Mar 31, 2022 | 597.03M | 70.20M | 13.32% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sigachi Industries | 4.86B |
| Balaxi Pharmaceuticals | 2.70B |
| Valiant Laboratories | 2.37B |
| Bafna Pharmaceuticals | 1.51B |
| Vaishali Pharma | 1.09B |
| Alpa Laboratories | 1.06B |
| Par Drugs and Chemicals | 1.04B |
| Vivimed Labs | 883.92M |
Krebs Biochemicals & Industries News
- 1 year ago - Krebs Biochemicals & Industries halts production following order from Andhra Pradesh Pollution Control Board - Business Upturn